Business Wire

Decision Intelligence Highlighted at Israel Hi-Tech Conference 2022

8.9.2022 15:00:00 EEST | Business Wire | Press release

Share

Israel Hi-Tech Conference 2022 recently put Decision Intelligence center stage, with main stage presentations from Omri Kohl, the CEO and co-founder of Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, and Dr. Lorien Pratt, Chief Scientist at Quantellia and the co-inventor of Decision Intelligence. Their presentations set out how the growing field of Decision Intelligence is taking artificial intelligence (AI) and analytics to the next level, and formed part of a packed agenda of events. This year’s conference focused on the opportunities created by AI and featured speakers from technology giants including Dell, Google, and NVIDIA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220908005304/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Omri Kohl, Chief Executive Officer, and Co-Founder, Pyramid Analytics: “Decision Intelligence is built on the principle that you should not need a background in data science to access the benefits of advanced analytics. At Pyramid, we are committed to automating the decision process to empower anyone to make faster, more intelligent decisions with any data, for any person and any analytics need." (Photo: Business Wire)

Key Points:

  • Dr. Pratt outlined why Decision Intelligence is the link to connect decision makers with data and analytics, addressing the persistent underutilization of data-driven insights by businesses today.
  • Decision Intelligence platforms have the potential to solve a range of previously vexing problems such as climate change, societal inequalities, and complex business problems.
  • Unlike some ML-driven analytic tools concerned with completely automating analysis, Decision Intelligence platforms augment human cognition.
  • According to Gartner® research, Decision Intelligence will be used by one-third of all large organizations by next year.
  • Global Spending on Big Data and Analytics Solutions is surging: IDC estimates it hit $215.7 billion in 2021 and it will have 12.8% compound annual growth rate 2021-2025.

Dr. Pratt is a leading voice on AI and analytics today. With a background in machine learning, she spearheaded several major breakthroughs, most notably the invention of transfer learning. Today she is one of the leading visionaries on Decision Intelligence, having recently published a book on the topic: How Decision Intelligence Connects Data, Actions and Outcomes for a Better World.

Her address at Hi-Tech Conference 2022 outlined a persistent problem in the tech industry: technology is not solving the problems we need it to. AI and Machine learning revolutionized how computers were programmed, allowing for rapid process and analysis of data at scale. However, Dr. Pratt told the attendees, ML can only label and predict, it cannot model causal connections on its own. It does not join up actions and outcomes, leaving a fundamental gap between analytics and decision makers.

Decision Intelligence is crucial in moving from actions to outcomes. Dr. Pratt underlined how it bridges the gap from decision makers to data analytics and AI, providing them with rapid access to the insights they need to tackle the most pressing, complex, and often unsolved, issues we face today. Decision Intelligence is about letting humans work together with analytics, data, and more to use AI for strategic, operational, and tactical decisions, from the C Suite to the front line.

A $200 Billion+ Market
The growth potential of Decision Intelligence is enormous. Gartner predicts that “more than 33%” of large organizations will be using Decision Intelligence by 2023. Similarly, worldwide spending on big data and business analytics (BDA) solutions was forecast to reach $215.7 billion in 2021, an increase of 10.1% over 2020, according to a recent update from IDC. The compound annual growth rate (CAGR) for global BDA spending over the 2021-2025 forecast period is predicted to be 12.8%.

Pyramid is helping to define this growing market. On the back of a recent oversubscribed US $120M Series E funding round, Omri Kohl appeared at this year’s conference in Israel to showcase Pyramid Analytics’ commitment to ensure everyone – even if they don’t have a technical background in analytics or data science – can access faster and more informed decisions.

Decision Intelligence is the Next Big Data Analytics Innovation
Artificial Intelligence (AI) is an increasingly important analytics technology. But AI to date is limited to highly-trained practitioners, and until now, there has been no easy way to integrate the essential AI components of Data Prep, Business Analytics, and Data Science. Pyramid solutions meet this need: its Decision Intelligence solutions go beyond traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. Pyramid’s platform lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.

In particular, the Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.

Quotes
Omri Kohl , Chief Executive Officer, and Co-Founder, Pyramid Analytics: “Decision Intelligence is built on the principle that you should not need a background in data science to access the benefits of advanced analytics. At Pyramid, we are committed to automating the decision process to empower anyone to make faster, more intelligent decisions with any data, for any person and any analytics need. It was a true pleasure to hear Dr. Pratt’s motivating talk at this year’s conference. She made Decision Intelligence, and its benefits, real and relatable for the audience, and everyone left the talk motivated to turn her inspiring words into reality.”

Dr. Lorien Pratt , Chief Scientist and Co-Founder, Quantellia LLC: “The shift represented by Decision Intelligence can be thought of in a similar manner to when we took computer technology out of hidden rooms and onto our desks and into our pockets. This is a once-in-a-generation moment, democratizing access to AI and data analytics – technology once reserved exclusively for the tech giants of our age. It gives us a framework for decision makers and data scientists to come together and ensure technology can be put to work in solving problems. It is a new way of thinking for organizations: rather than starting by thinking about the data you have, it asks us all to begin by asking what outcomes we want and what actions can be taken to achieve those outcomes, and then to fit the data into this action-to-outcome pathway.

“It was my pleasure to join so many talented individuals at this year’s Hi-Tech Conference. It was a fantastic event that demonstrated that the DI and AI sector is in robust health. I cannot wait to see Decision Intelligence continue to grow and expand. Far from eliminating the human element of work, Decision Intelligence augments the capabilities of ordinary workers, empowering them to solve the biggest problem of our age.”

About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for anyone to make faster, more intelligent decisions. The Pyramid Decision Intelligence Platform provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.

Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
UK

Alex Izza
Resonance
+44 759 189 9654
pyramidanalytics@resonancecrowd.com

US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com

Chas Kielt
Vice President of Global Corporate Communications, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye